Member Info for HedgeHogarth

Before I start, well done to the moderators of LSE who have committed to keeping a close eye on the HEMO forum following feedback from myself and a few other shareholders. It looks like they deleted a post today which was blatantly disruptive.

Here is my 'Objective' view as a well researched shareholder - going into the AGM tomorrow:

Current Share Price

Undervalues the company's progress significantly the company is very close to entering the clinic with it's lead candidate with a market Cap of £20m - which sits well below most comparable companies. Not all of #HEMO's eggs are in one basket - it also had CBR and CDX which have huge potential as well.

However. LTHer have claimed the SP is very low for a long time. The current market does not look favourably on small companies with high risk. The Biotech sector has also been in the doldrums for a while. Finally, the UK market has been accused of not valuing Biotech to the same degree as global markets.

The recent placing raised £4m at 2.5p. This is good recent benchmark. Since the placing, there has been lots or great news (Successful completion of CAR-T manufacturing runs, significant award of Options to CEO, +submission of IND) but also the recent clinical hold.

If you a confident that the clinical is a short-term blip - I would suggest that 3p is a good target

If you are concerned that the clinical hold is more serious - you may be best waiting for the update from Hemo on why they are confident in resolving it. 1.5p to 2p does still feel reasonable, even cheap with those concerns

CAR-T

Hemo have advanced CAR-T from the lab (H2 2019) to IND submission (H1 2023) and are now ready for clinical trials

Historically CAR-T has not proved successful on AML - unlike ALL and other cancers. This is the opportunity that Hemo are pursuing . They have been working in tandem with PENN University whose lead scientist was responsibility for the first two FDA approve CAR-T therapies.

Hemo have identified a new protein to target and have Patented this approach. They did a huge amount of work in 2021 on the safety aspects of the therapy and are now ready for clinical trails.

Having submitted the IND in May, the FDA were not ready to permit Hemo to start clinical trials at the end of the 30 review period. Therefore they place a clinical hold on CAR-T - Most clinical holds are lifted within the first 4-5 months and Hemo have stated in an RNS that they are confident of resolving any FDA issues. Infact, they believe they knw the main issue and have already been working on it.

That said, the market does not yet know what the reason for the Clincial Hold; more importantly the market does not know how long it will take Hemo to resolve.

Hemo have been waiting for the formal FDA feedback - which is sent by letter within 30 days of the clinical hold. If they have not received it yet, it should arrive before the middle of next week.

Continued >>>>

Socialist - my suspicion is that LSE have removed a meaningful number of posts from these members

If that were to be the case, I would argue that these members are then visible to LSE has persistent offenders and should then be subject to additional checks and observation.

I cannot attend AGM is person and I wil lbe attending a Sports Day

I am aware of a shareholder update and webcast of AGM

There is always the chance of an AGM statement appearing on Friday morning as an RNS. They seem to occur about 20% for small caps

You lucky thing Tilly - Can i be your friend ? ;-)

I'll bring the Grog

Good shout Mr India - hopefully in H2 we will get a handful of them

But as we all know, this is Biotech, the rewards are there for getting it right.

That smart chap Aesop knew what investing in Biotech was like when he wrote the Tortoise and the Hare.

Vlad fleetingly shared an update yesterday that showed further failure of the tradition CAR-T approached for AML.

A persistent challenge for Sponsors trying to develop a successful CAR-T therapy for AML is cytokine release syndrome, a hard-to-predict issue that has arisen during clinical trials.

Hemo's solution which targets FLT3/FLK2 receptor (protein that is found on the surface of AML cells) is designed to overcome this key safety issue.

Hemo talked a lot about SAFE CAR-T in 2021 and how they were working on a tune-able solution. It is not 100% clear to me if this work formed part of the IND - I have submitted this question ahead of AGM / Shareholder update.

LSE has also kindly agreed to keep a closer eye on this specific forum following my correspondence

It is very difficult to moderate a forum as popular , complex and busy as LSE. It is absolutely fine to post negative comments about Hemo, even o a regular basis. However, if part of a more collective and orchestrated attempt to manipulate the share price or to stimulate an abnormal short term movement - I will argue strongly that it constitutes attempted price manipulation which would interest the FCA.

The best way for forums to work is through self moderation - non disruptive and manipulative members need to work harder to keep this forum clean and a place when genuine traders and investors want to spend time. (Yes, traders too)

I disagree Mr India - not the first time I hear you sight ;-)

These 'dark forces' who attempt to orchestrate disproportionate and abnormal movements in the share price need to be stopped. They thrive on updates from Hemo - they either pick them apart deliberately or they use the good updates to 'rinse and repeat'.

In my conversations with this website - I enquired about how forum users can be better vetted/validated. They replied to say they are looking to hopefully introduce more checks regarding newly registered users that would potentially require more information so we're able to better identify who users are that post on Share Chat.

I have no beef with LSE - I think the forum is a great place to converse with other shareholders and exchange ideas, discuss the risks and opportunity and the opportunity to hear other peoples' perspectives. However, what I have witnessed now on many occasions (and not just on HEMO) is orchestrated attempts to manipulate the narrative and ultimately the share price by a Ringleader that may have more than 1 alias and more than 1 accomplice. Look at Tuan- the way in which they try to suggest they do not have a hold on the English language is frankly embarrassing,

It is very difficult to moderate this forum - but I believe that more needs to be done. It seems to be that each post is moderated in isolation - I do not see evidence that the website is looking at patterns of behaviour.

I'm a big fan of LSE and have subscribed to premium content for a while. But I have made the decision to cancel my subscription and go elsewhere. I'm not a hypocrite and cannot be seen to fund the site in which i believe is the vehicle for the suspected price manipulation that i have observed.

Hemo will release news when it is appropriate to do so - when/if the news is as positive as many LTHers hope, I have no doubt it will have a very positive effect on the shareprice. I do not think that just sharing news is credible or a solution. You claim to have a long memory - how many times have Hemo released good news that shows further development and a move closer to their ultimate goal - and yet made no impact on the share price.

Thanks Cyrox - that is great advice and Intel

The mapping of activity of the chief protagonist and the share price action certainly makes people take a second look...

I'm determined to not let this rest.

It is not right - It impacts the company and shareholders

I'm still waiting for a response from LSE - I have asked how many posts they have indeed removed from a few named individuals. If i do not get an an answer within a few days, perhaps it is something I could pursue Via the freedom of information act

Sigh...

More screen prints required for my FCA complaint #stopthetrolls

I will be continue to capture evidence between now and the AGM - (screen shots of this forum)

Periods of activity and non activity by certain posters

This is purely my opinion - but in the event that the FCA do investigate or take a closer at this suspicious activity I imagine they will look very carefully at those who are selling shares today - especially those big blocks!

TTFN

I can back for a week or so - because STU485 and his multiple alias' had disappeared.

Now they are back - to try their hardest to CONTROL the narrative on this forum. This creates frustration and disruption to the many on here who are well researched and Hemo shareholders.

Sadly, LSE appear to have no solution to avoid this happening. The only thing you can do is FILTER them all and that way you only see posts from non manipulative posters.

The truth is STU does not know anything more than any of you do. He is speaking complete and utter rubbish in order to try and frame his own agenda and any accomplices. It even got as 'subtle' this time as one his partners in crime or another alias of his suggested just sell your shares and buy them back after the deramp. STU alywas comes on this forum and predicts the worst - there was concern from some on this board that he had access to insider information when suggesting a Clincial Hold had been placed. This was just his 1 in a 100 moment - for years he just predicts the worse to suit his agenda and this was one of the very few times it transpired.

For me, the behaviour of who ever is behind the alias of STU485 and other aliases amounts to a calculated and concerted attack on the shareprice, to manipulate the share price and based on my interpretation of the FCA handbook - this is a CRIIMINAL offence.

My advice to Shareholders is to AVOID responding to these posters and ignore them. I have alerted the company and the FCA to the activity. (Complete with screen shots etc)

For the record, my opinion as a relatively well researched shareholder. I am 100% certain that Hemo will wait till receiving the FULL FDA FEEDBACK before formally updating the market. It is AGM week, so they is a chance we get an AGM statement RNSd on the morning of the AGM - I guess there is a chance it may allude to clinical hold but it will not add any more to what we already know unless Hemo has received, digested and understood the full extent of feedback from FDA - however straightforward or complex that turns out to be.

In the meantime, we know that based on conversations with the FDA, they are very confident and already addressing what they believe the key issue is. Anything else you read or hear is PURE speculation.

Looking forward to the week with optimism.

AGM and some shareholder engagement this week should give us the chance to learn a little more about the current progress on all three fronts.

Hemogenyx will update the market in line with LSE regulations. They do not and will not update the market in CAR-T until they receive the detailed feedback from the FDA.

I will choose my words carefully in respect of the multiple posts this weekend from members I have filtered. I will not share my thoughts or opinions - I will just share this link to the FCA rules on price manipulation. I have alerted the company and the FCA to these messages which I believe amount to abuse.

https://www.handbook.fca.org.uk/handbook/MAR/1/6.html?date=2016-03-07

Tilly - if you had waited a few minutes you could have included the 1m (Buy at a premium) Kipper at 9:39 (reported 1 hour later)

Hemoknowledge, quite possibly my favourite post of 2023 so far...

They think they know the main reason because of the engagement with FDA after the submission.

Stick to the facts HT

It is not a stupid comment.

Why would I blame someone if I did not not what has happened or what may have caused it

No worries Micky. Chin up mate. Vlad's race is far from over, his story is not written yet. Let's see where we are in 1 year, 3 years and 5 years....

HemoTruth - I don't blame anyone for clinical hold. I don't even know the reason for it yet. It may transpire that it was unavoidable or could not have be foreseen.

Micky - Your attitude towards Vlad is hard to understand. It seems like you have listened too much to the de-rampers in recent months.

He may not be everyone's cup of team as CEO, but he has led the team to great things in the last 12 months.

- Looks like he has recruited a highly motivated, skilled team

- In spite of Covid, they have taken CAR-T from the lab at the start of 2020 to the brink of the clinic in 2023

- secured new premises with certified clean rooms

- completed all the research, development and manufacturing stages of taking CAR-T to the clinic

- moving CDX and CBR forward whilst trying to keep CAR-T as a priority

- Raised £4m in a difficult market for small companies to raise - at a 100% premium to the 12mth prevailing avg share price

- Continued to network well, court partners, collaborate with some key third parties

The clinical Hold is the only fly in the ointment - but we don't know much about that yet, Vlad remains confident that they will overcome it and take CAR-T into the clinic. I find it hard to lay the blame on Vlad for the clinical hold

I'm invested because of Vlad - I remain a content, optimistic and confident in Vlad and his team.